CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 5, 2019--
Synlogic,
Inc. (Nasdaq:
SYBX), a clinical stage company applying synthetic biology to
probiotics to develop novel, living medicines, announced today that the
Company will release its fourth quarter and full year 2018 financial
results before the market opens on Tuesday, March 12, 2019. The press
release will be followed by a conference call at 8:00 am ET, which will
be open to the public via telephone and webcast. During the conference
call, the Company will review its financial results and provide a
corporate update.
The conference call dial-in numbers are (844) 815-2882 for domestic
callers and (213) 660-0926 for international callers. The conference ID
number for the call is 2181868. Participants may access the live webcast
via a link on the Synlogic website in the Events
Calendar of the Investors and Media section. For those unable to
participate in the conference call or webcast, a replay will be
available for 30 days on the Company's website.
About Synlogic
Synlogic is pioneering the development of a
novel class of living medicines, Synthetic Biotic medicines, based on
its proprietary drug development platform. Synlogic leverages the tools
and principles of synthetic biology to genetically engineer beneficial
microbes to perform or deliver critical functions missing or damaged due
to disease. Synthetic Biotic medicines are designed to act locally and
have a systemic effect to address disease in patients. Synlogic’s two
lead programs, SYNB1020 and SYNB1618, are orally administered and target
hyperammonemia as a result of liver damage or genetic disease, and
phenylketonuria, respectively. Synlogic is also developing SYNB1891 as
an intratumorally-administered Synthetic Biotic medicine for the
treatment of cancer. In addition, the company is leveraging the broad
potential of its platform to create additional Synthetic Biotic
medicines for the treatment of liver disease, as well as inflammatory
and immune disorders including Synlogic’s collaboration with AbbVie to
develop Synthetic Biotic-based treatments for inflammatory bowel disease
(IBD). For more information, please visit www.synlogictx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190305005948/en/
Source: Synlogic, Inc.
Synlogic
Media Contact:
Courtney Heath
Phone:
617-872-2462
Email: courtney@scientpr.com
Investor Contact:
Elizabeth Wolffe, Ph.D.
Phone:
617-207-5509
Email: liz@synlogictx.com